Tocilizumab reduces the need for mechanical ventilation in severe Coronavirus Disease 2019 (COVID19); the Greek Experience in a pragmatic clinical setting
G. Hardavella (Athens, Greece), E. Bellou (Athens, Greece), E. Keramida (Athens, Greece), N. Papaioannou (Athens, Greece), I. Bracka (Athens, Greece), S. Mazarakis (Athens, Greece), I. Karampinis (Athens, Greece), N. Anastasiou (Kifissia, Athens, Greece), X. Theiakos (Athens, Greece), P. Demertzis (Athens, Greece)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2604
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Hardavella (Athens, Greece), E. Bellou (Athens, Greece), E. Keramida (Athens, Greece), N. Papaioannou (Athens, Greece), I. Bracka (Athens, Greece), S. Mazarakis (Athens, Greece), I. Karampinis (Athens, Greece), N. Anastasiou (Kifissia, Athens, Greece), X. Theiakos (Athens, Greece), P. Demertzis (Athens, Greece). Tocilizumab reduces the need for mechanical ventilation in severe Coronavirus Disease 2019 (COVID19); the Greek Experience in a pragmatic clinical setting. 2604
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|